参考文献/References:
[1]Grimm PD, Blasko JC, Sylvester JE, et al.10year biochemical (prostatespecific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys, 2001,51(6):31-40.
[2]Hu K, Wallner K. Clinical course of rectal bleeding following I125 prostate brachytherapy. Int J Radiat Oncol Biol Phys,1998,41(2):263-265.
[3]王俊杰.放射性粒子种植治疗前列腺癌.中国微创外科杂志,2002,2(2):82-84.
[4]Kang SK, Chou RH, Dodge RK, et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys,2002,53(1):99-103.
[5]Sherertz T, Wallner K, Merrick G,et al. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. Brachytherapy,2004,3:130-135.
[6]Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol,2002,41(4):427-433.
[7]Gelblum DY, Potters L. Rectal complications associated with transperineal brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys,2000,48(1):119-124.
[8]Lane BR, Stein DE, Remzi FH, et al. Management of radiotherapy induced rectourethral fistula.J Urol,2006,175:1382-1388.